The Preemptive Analgesic Efficacy of Nefopam

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02561468

Enrollment

Registered

2015-09-28

Start date

2015-04-30

Completion date

2016-01-31

Last updated

2016-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasm

Brief summary

Nefopam is administered as a preemptive analgesic drug to the patient undergoing breast cancer surgery. It will be evaluated whether postoperative acute and chronic pain can be reduced.

Interventions

DRUGNefopam

DRUGSaline

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients diagnosed with breast cancer * Lumpectomy with axillary lymph node dissection or Lumpectomy with sentinel lymph node biopsy * American Society of Anesthesiologists physical status I or II

Exclusion criteria

* Refusal * Seizure * Cardiac disease * Monoamine oxidase inhibitor user * Urologic disease * Glucoma * Preoperative analgesic drug medication * Pregnancy * Recurred breast cancer patient

Design outcomes

Primary

Measure	Time frame
The change of pain numerical rating score from postoperative 30 min until postoperative 3 month	Postoperative 30 min, postoperative 1 day, postoperative 1 week, postoperative 3 month

Secondary

Measure	Time frame
The dose of ketorolac administered to the patient.	postoperative 1 day

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026